arrow
M

Murat Duranay

ankara training and research hospital
H指数:20
被引数:2,727

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Finerenone Use in Heart Failure Patients with Type 2 Diabetes and Kidney Disease: An Analysis of the FINE-TURK Registry

非奈利酮在合并2型糖尿病和肾脏疾病的心力衰竭患者中的使用:FINE-TURK登记研究的分析

2026-09-100
PRE
Histopathological predictors of renal outcomes in idiopathic membranous nephropathy with a focus on global sclerotic glomeruli ratio

特发性膜性肾病的肾脏结局的病理预测因子,重点关注全球硬化肾小球比率

2026-07-250
OAAI
Hyperkalemia Risk After Finerenone Initiation in Diabetic Kidney Disease with Elevated Baseline Potassium: A Multicenter Cohort Study

在糖尿病肾病合并基线钾水平升高患者中,启动非奈利酮治疗后的高钾血症风险:一项多中心队列研究

2026-07-240
OAAI
Hyperkalemia risk with finerenone in diabetic kidney disease: a real-world analysis from the FINE-TURK cohort

使用非奈利酮治疗糖尿病肾病患者的血钾升高风险:FINE-TURK队列的真实世界分析

2026-07-060
OAAI
Sex Differences in Baseline Characteristics and Long-Term Outcomes of Primary Glomerular Diseases: Insights from the TSN-GOLD Registry

原发性肾小球疾病基线特征和长期结局的性别差异:TSN-GOLD注册研究中的启示

2026-05-220
OA
Prognostic factors and validation of the histologic chronicity score for C3 glomerulopathy: a registry analysis
2024-03-200
OAAI
Uric Acid Induces Hepatic Steatosis by Generation of Mitochondrial Oxidative Stress POTENTIAL ROLE IN FRUCTOSE-DEPENDENT AND -INDEPENDENT FATTY LIVER

尿酸通过产生线粒体氧化应激电位诱导肝脂肪变性在果糖依赖性和非依赖性脂肪肝中的作用

2012-11-01602
OAAI